Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility

被引:2
|
作者
Hanai, Toshihiko [1 ]
机构
[1] Res Inst Prod Dev, Hlth Res Fdn, 4F,Sakyo Ku, Kyoto 6060805, Japan
关键词
SARS-CoV-2 Omicron variants (BA.4; BA.5; BA.2.75; BQ.1; BQ.1.1); ACE-2; Binding strength; Quantitative in silico analysis; Molecular interaction energy; Binding inhibitor; PROTEASE;
D O I
10.1016/j.talanta.2022.124127
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The Covid-19 variants' transmissibility was further quantitatively analyzed in silico to study the binding strength with ACE-2 and find the binding inhibitors. The molecular interaction energy values of their optimized complex structures (MIFS) demonstrated that Omicron BA.4 and 5's MIFS value (344.6 kcal mol(-1)) was equivalent to wild-type MIFS (346.1 kcal mol(-1)), that of Omicron BQ.1 and BQ. 1.1's MIFS value (309.9 and 364.6 kcal mol-1). Furthermore, the MIFS value of Omicron BA.2.75 (515.1 kcal mol(-1)) was about Delta-plus (511.3 kcal mol(-1)). The binding strength of Omicron BA.4, BA. 5, and BQ.1.1 may be neglectable, but that of Omicron BA.2.75 was urging. Furthermore, the 79 medicine candidates were analyzed as the binding inhibitors from binding strength with ACE-2. Only carboxy compounds were repulsed from the ACE-2 binding site indicating that further modification of medical treatment candidates may produce an effective binding inhibitor.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 104
  • [32] Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
    Kimura, Izumi
    Yamasoba, Daichi
    Tamura, Tomokazu
    Nao, Naganori
    Suzuki, Tateki
    Oda, Yoshitaka
    Mitoma, Shuya
    Ito, Jumpei
    Nasser, Hesham
    Zahradnik, Jiri
    Uriu, Keiya
    Fujita, Shigeru
    Kosugi, Yusuke
    Wang, Lei
    Tsuda, Masumi
    Kishimoto, Mai
    Ito, Hayato
    Suzuki, Rigel
    Shimizu, Ryo
    Begum, Mst Monira
    Yoshimatsu, Kumiko
    Kimura, Kanako Terakado
    Sasaki, Jiei
    Sasaki-Tabata, Kaori
    Yamamoto, Yuki
    Nagamoto, Tetsuharu
    Kanamune, Jun
    Kobiyama, Kouji
    Asakura, Hiroyuki
    Nagashima, Mami
    Sadamasu, Kenji
    Yoshimura, Kazuhisa
    Shirakawa, Kotaro
    Takaori-Kondo, Akifumi
    Kuramochi, Jin
    Schreiber, Gideon
    Ishii, Ken J.
    Hashiguchi, Takao
    Ikeda, Terumasa
    Saito, Akatsuki
    Fukuhara, Takasuke
    Tanaka, Shinya
    Matsuno, Keita
    Sato, Kei
    CELL, 2022, 185 (21) : 3992 - +
  • [33] Renewed global threat by the novel SARS-CoV-2 variants 'XBB, BF.7, BQ.1, BA.2.75, BA.4.6': A discussion
    Mohapatra, Ranjan K.
    Mahal, Ahmed
    Kutikuppala, L. V. Simhachalam
    Pal, Madhumita
    Kandi, Venkataramana
    Sarangi, Ashish K.
    Obaidullah, Ahmad J.
    Mishra, Snehasish
    FRONTIERS IN VIROLOGY, 2022, 2
  • [34] Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
    Tuekprakhon, Aekkachai
    Nutalai, Rungtiwa
    Dijokaite-Guraliuc, Aiste
    Zhou, Daming
    Ginn, Helen M.
    Selvaraj, Muneeswaran
    Liu, Chang
    Mentzer, Alexander J.
    Supasa, Piyada
    Duyvesteyn, Helen M. E.
    Das, Raksha
    Skelly, Donal
    Ritter, Thomas G.
    Amini, Ali
    Bibi, Sagida
    Adele, Sandra
    Johnson, Sile Ann
    Constantinides, Bede
    Webster, Hermione
    Temperton, Nigel
    Klenerman, Paul
    Barnes, Eleanor
    Dunachie, Susanna J.
    Crook, Derrick
    Pollard, Andrew J.
    Lambe, Teresa
    Goulder, Philip
    Paterson, Neil G.
    Williams, Mark A.
    Hall, David R.
    Fry, Elizabeth E.
    Huo, Jiandong
    Mongkolsapaya, Juthathip
    Ren, Jingshan
    Stuart, David, I
    Screaton, Gavin R.
    CELL, 2022, 185 (14) : 2422 - +
  • [35] Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility
    Hanai, Toshihiko
    TALANTA, 2022, 240
  • [36] Efficacy of Tixagevimab/Cilgavimab Prophylaxis and Vaccination on Omicron Variants (BA.1, BA.2, BA.5, and BQ.1.1) in Kidney Transplant Recipients
    Bertrand, Dominique
    Laurent, Charlotte
    Lemee, Veronique
    Lebourg, Ludivine
    Hanoy, Melanie
    Le Roy, Frank
    Nezam, Dorian
    Pruteanu, Diana
    Grange, Steven
    de Nattes, Tristan
    Lemoine, Mathilde
    Candon, Sophie
    Guerrot, Dominique
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1343 - 1345
  • [37] Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab
    Fujita, Shigeru
    Kosugi, Yusuke
    Kimura, Izumi
    Yamasoba, Daichi
    Sato, Kei
    VIRUSES-BASEL, 2022, 14 (12):
  • [38] Commentary on 'Implications of the SARS-CoV-2 subvariants BA.4 and BA.5'
    Khani, Elnaz
    Entezari-Maleki, Taher
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (01) : 75 - 76
  • [39] Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
    Bellusci, Lorenza
    Grubbs, Gabrielle
    Sait, Shaimaa
    Yonker, Lael M.
    Randolph, Adrienne G.
    Novak, Tanya
    Kobayashi, Takuma
    Khurana, Surender
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [40] Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
    Lorenza Bellusci
    Gabrielle Grubbs
    Shaimaa Sait
    Lael M. Yonker
    Adrienne G. Randolph
    Tanya Novak
    Takuma Kobayashi
    Surender Khurana
    Nature Communications, 14